Wuhan Wuyao Pharmaceutical Co., Ltd. is a holding subsidiary invested by Yuanda (China) Co., Ltd. (formerly Wuhan Pharmaceutical Factory) in 2002. It is a well-known enterprise in the production and operation of characteristic raw materials in China. The company passed the acceptance of "safety production standardization secondary enterprise"; in the same year, it was rated as "high-tech enterprise" in Hubei Province; the annual sales revenue was 0.6 billion yuan, and the products were exported to more than 40 countries and regions such as Europe and the United States, with an annual export value of 50 million US dollars.
According to the Wuhan Municipal People's Government's "Opinions on Accelerating the Relocation and Remediation of Chemical Production Enterprises in the Third Ring Road of Our City" (Wu Zheng [2008] No. 50) and the overall plan, Wuhan Wuyao Pharmaceutical Co., Ltd. moved to Hubei Province as a whole. Chemical Industrial Park, Fuchi Town, Yangxin County, Huangshi City. The company has 820 employees and 500 technical and management personnel above junior college. With a registered capital of 61 million yuan, the company is a high-tech enterprise engaged in the production and operation of raw materials.
Since its establishment, the company has adhered to the principle of "improving good products and cultivating high levels". It has developed from bulk bulk raw materials such as analgin, metronidazole and chloramphenicol to characteristic raw materials. Its main production series are tirofiban hydrochloride, norepinephrine bitartrate, epinephrine, enoxacin, methoxamine hydrochloride, hydroxychloroquine sulfate, pirnoxine sodium, glipizide and other characteristic raw materials such as well as drug intermediates. Among them, enoxacin is the first class II new drug after the promulgation of China's Drug Law, tirofiban hydrochloride is a national "Torch Plan" project, and pirnoxine sodium and norepinephrine bitartrate series products are exclusively produced in the country. The company seizing the opportunity of "transfer, transformation and turning around", the members of the production and management team are of one heart and one mind, and strive to move forward.
With the vision of "becoming a pharmaceutical company respected by Chinese doctors and patients and restoring it to society", the company abides by the core values of "providing good products and cultivating high levels", and its products cover raw materials and intermediates. Enterprises follow the development direction of product operation, that is, adhere to the "ophthalmology, cardiovascular, anti-bacterial and anti-inflammatory, antipyretic and analgesic, liver-protective characteristic raw materials. Be a pharmaceutical company, be a responsible pharmaceutical company that is respected by doctors and patients, and become a world-renowned supplier of specialty APIs. With its profound historical accumulation, Wuyao Pharmaceutical has long been listed as a designated enterprise for emergency drugs and narcotics in the national combat readiness reserve, and its products such as dimercaptopropanol have been rated as "conscience medicine" and "reassurance medicine" by the industry ".
In the next five years, the company will build a domestic API industry chain through new specialty APIs and biopharmaceuticals, and become a world-wide specialty API supplier, making new contributions to people's lives and health.
